Vanderbilt University Medical Center Studies Provide Key Positive Results for COVID-19 Vaccine in Early-Stage Clinical Trial
July 15, 2020
July 15, 2020
NASHVILLE, Tennessee, July 15 -- Vanderbilt University Medical Center issued the following news:
An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.
The vaccine, called mRNA-1273, was developed by Moderna Inc. in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes . . .
An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.
The vaccine, called mRNA-1273, was developed by Moderna Inc. in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes . . .